MAPT and Alzheimer disease: Although earlier work indicated that Aβ pathology may reach a plateau during the dementia phase of AD,47 recent findings suggest that this may not be the case.48 As such, we were not able to examine the effect of higher Aβ-PET SUVR values on p-tau isoforms but were nonetheless able to identify the significantly higher dynamic range of p-tau217Lilly using the available Aβ-PET from participants with out dementia.